Sara Makrinos, PA
Medical · Glen Burnie, MDNPI 1942606462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 734 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 734 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Collegium Pharmaceutical, Inc.$1K
- Lundbeck LLC$347
- Abbott$334
- plus $3K from 27 others
What the payments were for
- Food & beverage$11,198100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 146 | $2,685 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 253 | $2,382 |
| AbbVie(2 entities) | 111 | $1,701 |
| Collegium Pharmaceutical, Inc. | 98 | $1,220 |
| Lundbeck LLC | 17 | $347 |
| Abbott | 10 | $334 |
| Vertos Medical, Inc. | 6 | $330 |
| Amgen(2 entities) | 17 | $307 |
| Pfizer | 12 | $293 |
| Nevro Corp. | 7 | $232 |
| Averitas Pharma Inc. | 9 | $218 |
| Medtronic | 2 | $194 |
| GRT US Holding, Inc. | 6 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $80 |
| Redhill Biopharma Inc. | 5 | $77 |
| Lilly USA, LLC | 4 | $75 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| International Rehabilitative Sciences, Inc | 1 | $56 |
| Relievant Medsystems, Inc. | 1 | $56 |
| Tonix Medicines, Inc. | 2 | $55 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Globus Medical | 2 | $44 |
| Electronic Waveform Lab, Inc. | 3 | $35 |
| IBSA Pharma Inc. | 2 | $33 |
| Nalu Medical, Inc. | 2 | $29 |
| Si-bone, Inc. | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Biotronik NRO, Inc. | 1 | $23 |
| Valinor Pharma, LLC | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$170
- WaveWriter Alpha Prime 16$129
- mild Device Kit$117
- Omnia$109
- WAVEWRITER ALPHA$104
How this compares
$11,198 in reported general payments places this provider in the 95th percentile of 543 medical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 28 | $66,548 |
| UbrelvyUbrogepant | 37 | $61,263 |
| BelbucaBuprenorphine Hcl | 72 | $53,661 |
| OxycontinOxycodone Hcl | 92 | $38,283 |
| Xtampza ErOxycodone Myristate | 59 | $31,828 |
| Oxycodone Hcl | 1,321 | $24,191 |
| Emgality PenGalcanezumab-Gnlm | 24 | $23,393 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 868 | $21,620 |
| QuliptaAtogepant | 20 | $21,047 |
| SymproicNaldemedine Tosylate | 28 | $17,742 |
| Nucynta ErTapentadol Hcl | 18 | $17,028 |
| Gabapentin | 643 | $11,629 |
| NucyntaTapentadol Hcl | 12 | $11,245 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 535 | $10,994 |
| Buprenorphine | 44 | $10,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er, Nucynta | $1,220 | $113,762161 claims |
| AbbVieUbrelvy, Qulipta, Linzess | $1,701 | $92,42673 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,382 | $66,54828 claims |
| Redhill Biopharma Inc.Movantik | $77 | $5,72214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 medical providers in Maryland.
Other medical in Glen Burnie
- Cherish HannahGlen Burnie$11K
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.